Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.

@article{Fuchs2013IntentionsTU,
  title={Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.},
  author={Jonathan D. Fuchs and Magdalena E. Sobieszczyk and Tamra Madenwald and Doug Grove and Shelly Tanner Karuna and Michele Peake Andrasik and Adam I Sherwat and Gail B. Broder and Kenneth Mayer and Beryl A Koblin and Scott M. Hammer},
  journal={Journal of acquired immune deficiency syndromes},
  year={2013},
  volume={63 3},
  pages={259-62}
}
In November 2010, the iPrEx study reported that preexposure prophylaxis (PrEP) with daily tenofovir disoproxil fumarate/emtricitabine reduced HIV infections by 44% among men who have sex with men and subsequent trials corroborated efficacy among heterosexual men and women. During regularly scheduled follow-up visits from January to March 2011, participants in an ongoing phase 2b vaccine efficacy trial completed an anonymous Web survey about PrEP. Among 376 respondents, 17% reported they were… CONTINUE READING